Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Ignite Investment Summit (October 2026)
25 slides from Proteomics International Laboratories's conference presentation, Oct 14, 2026
Slide 1: Ignite Investment Summit: Disciplined Path to Commercial Success
Proteomics International Laboratories Ltd rsonal use only Ignite Investment Summit Disciplined Path to Commercial Success 14 October 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Slide 2: Disclaimer
Disclaimer rsonal use only This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associa
Slide 3: Executive Summary: Disciplined Path to Commercial Success
EXECUTIVE SUMMARY Disciplined Path to Commercial Success rsonal use only Proteomics International has repositioned the business for commercial execution, advancing three lead tests through validation, market access and reimbursement pathways, while maintaining disciplined capital allocation. Transfo
Slide 4: About Us
COMPANY OVERVIEW About Us rsonal use only Proteomics International (ASX: PIQ) develops proprietary blood tests for disease prediction and diagnosis. We deliver laboratory testing and clinical reporting, while distribution partners provide market access to clinicians and patients. Target Unmet Levera
Slide 5: Board of Directors
COMPANY OVERVIEW Board of Directors rsonal use only Dr James Williams Non- David Morris Aaron Brinkworth Paul House Vicki Robinson Executive Chair CEO & Managing Director Non-Executive Director Non-Executive Director Non-Executive Director PhD, MBA, BSc (Hons) GAICD BBus, BAppSc, GAICD BHIthSc, GAIC
Slide 6: Science of Proteomics
PLATFORM Science of Proteomics rsonal use only Genes carry the instructions. Proteins reveal how those instructions play out in health and disease. Translating that insight into reliable diagnostic and prognostic tests requires precision, standardisation and deep technical expertise. Genes Provide P
Slide 7: Innovation Portfolio – Four Tests
PORTFOLIO Innovation Portfolio – Four Tests rsonal use only Proteomics International provides a suite of four prognostic and diagnostic tests targeting specific clinical areas of unmet need. Our priority is to validate and commercialise these tests before developing new tests for other medical condi
Slide 8: Innovation Portfolio – Promarker Tests
PORTFOLIO Innovation Portfolio – Promarker Tests rsonal use only The Promarker Portfolio tests address distinct clinical pathways, supporting earlier risk identification, more targeted referral and more efficient use of healthcare resources. Promarker D Promarker Eso Promarker Endo Clinical Identifi
Slide 9: Innovation Portfolio – Market Potential
MARKET POTENTIAL Innovation Portfolio – Market Potential rsonal use only We have assessed the market opportunities for our three primary tests in both Australia and the United States. Our analysis indicates that the serviceable obtainable market opportunity is substantial, offering significant growt
Slide 10: Patient Care Ecosystem
CLINICAL PATHWAY Patient Care Ecosystem rsonal use only The patient journey involves clear roles for patients, clinicians, distributors, and labs. Proteomics International handles development and testing, while partners manage market access, ensuring accountability and quality from collection to res
Slide 11: Healius Distribution Partnership
DISTRIBUTION MODEL Healius Distribution Partnership rsonal use only Exclusive Australian pathology distribution for the Promarker® portfolio. Healius provides national market access through its collection network and referrer relationships, while Proteomics delivers testing and clinical reporting. S
Slide 12: Strategic Framework for Execution
ENTERPRISE PRIORITIES Strategic Framework for Execution rsonal use only Enterprise objectives create a clear framework aligning strategy with execution, focusing on areas of commercial execution, innovation, operations, and organisational capabilities to deliver lasting value for patients, partners,
Slide 13: Execution Plan – The Next Years
STRATEGIC ROADMAP Execution Plan – The Next 3 Years rsonal use only The strategic roadmap outlines the 3 year plan focused on commercialisation, fostering innovation, scaling processes and infrastructure, and enhancing our capabilities to achieve sustainable long term value. RESET ACCESS ADVANCE ACC
Slide 14: Appendix
Proteomics International Laboratories Ltd rsonal use only APPENDIX 14 October 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Slide 15: Promarker D – Chronic Kidney Disease
PRODUCT OVERVIEW Promarker D – Chronic Kidney Disease rsonal use only Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, enabling earlier clinical intervention and ongoing monitoring. Clinical Value Market Opportunity Key Action
Slide 16: Promarker D Patient Journey
PATIENT JOURNEY Promarker D – Chronic Kidney Disease rsonal use only Promarker D enables a shift from reactive CKD treatment to proactive risk-based care, identifying risk earlier, guiding targeted intervention, and helping reduce late-stage cost burden. SYMPTOMS EVALUATION MANAGEMENT Risk Becomes V
Slide 17: Promarker Eso – Oesophageal Cancer
PRODUCT OVERVIEW Promarker Eso – Oesophageal Cancer rsonal use only Minimally invasive diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma, reducing the need for invasive surveillance endoscopy procedures. Clinical Value
Slide 18: Promarker Eso Patient Journey
PATIENT JOURNEY Promarker Eso – Oesophageal Cancer rsonal use only Promarker Eso could shift oesophageal cancer risk assessment from procedure-led surveillance to a faster, lower-burden blood-test triage pathway. SYMPTOMS EVALUATION MANAGEMENT Measurable Risk Insight Earlier Risk Stratification Targ
Slide 19: Promarker Endo – Endometriosis
PRODUCT OVERVIEW Promarker Endo – Endometriosis rsonal use only Diagnostic blood test for patients with symptoms suggestive of endometriosis, thus reducing the extensive delays in diagnosis and management. Clinical Value Market Opportunity Key Actions Identifies patients with a high risk of SOM refl
Slide 20: Promarker Endo Patient Journey
PATIENT JOURNEY Promarker Endo – Endometriosis rsonal use only Promarker Endo could shorten the path from symptoms to clarity, using a blood-test risk triage to support earlier referral and more targeted care. SYMPTOMS EVALUATION MANAGEMENT Symptoms Assessed Objectively Earlier Risk Stratification R
Slide 21: OxiDx – Oxidative Stress Platform
PRODUCT OVERVIEW OxiDx – Oxidative Stress Platform rsonal use only Proprietary platform for measuring oxidative stress, focusing on diagnostic or specialised applications where there is clear clinical value and economic benefits. Clinical Value Market Opportunity Key Actions Provides an objective me
Slide 22: Distribution Partnerships to Accelerate Adoption
DISTRIBUTION MODEL Distribution Partnerships to Accelerate Adoption rsonal use only The distributor model delivers faster adoption, lower execution risk, and superior capital efficiency compared to any direct or hybrid alternative. Characteristics of the Distribution Model Key Success Factors • Buil
Slide 23: Reimbursement Pathways – Australia
REIMBURSEMENT PATHWAYS Reimbursement Pathways – Australia rsonal use only Australia provides a national reimbursement framework for prognostic and diagnostic tests. Achieving Medicare Benefits Schedule (MBS) listing is a medium term objective that will serve as a significant driver of growth. Reimbu
Slide 24: Reimbursement Pathways – USA
REIMBURSEMENT PATHWAYS Reimbursement Pathways – USA rsonal use only In the United States, reimbursement for prognostic and diagnostic tests are decentralised and based on evidence, growing incrementally through private and public funding. Reimbursement Process Key Considerations • The USA has no uni
Slide 25: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd rsonal use only ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Proteomics International Laboratories — Ignite Investment Summit (October 2026) on 6ix